newsfilter
← Latest News
Business Wire·

Travere Therapeutics Reports Second Quarter 2026 Financial Results

Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million Enrollment of